Paper Search Console

Home Search Page About Contact

Journal Title

Title of Journal: Osteoporos Int

Search In Journal Title:

Abbravation: Osteoporosis International

Search In Journal Abbravation:

Publisher

Springer-Verlag

Search In Publisher:

DOI

10.1007/bf02640212

Search In DOI:

ISSN

1433-2965

Search In ISSN:
Search In Title Of Papers:

Costutility of longterm strontium ranelate treat

Authors: M Hiligsmann O Bruyère JY Reginster
Publish Date: 2009/04/07
Volume: 21, Issue: 1, Pages: 157-
PDF Link

Abstract

A validated Markov microsimulation model with a Belgian healthcare cost perspective was used to assess the cost per qualityadjusted lifeyear QALY of strontium ranelate compared to no treatment on a basis of calcium/vit D supplementation if needed Analyses were performed for women aged 70 75 and 80 years either with a bone mineral density Tscore ≤ −25 SD or with prevalent vertebral fractures The relative risk of fracture during therapy was derived from the Treatment of Peripheral Osteoporosis Study trial over 5 years of treatment Parameter uncertainty was evaluated using both univariate and probabilistic sensitivity analysesStrontium ranelate was costsaving at the age of 80 years in both populations For women with a Tscore ≤ −25 SD the costs per QALY gained of strontium ranelate were respectively €15096 and €6913 at 70 and 75 years of age while these values were €23426 and €9698 for women with prevalent vertebral fractures Sensitivity analyses showed that the results were robust over a wide range of assumptionsMickaël Hiligsmann has received research grant from Amgen Novartis and Servier and lecture fees and reimbursement for attending meetings from Servier Olivier Bruyère has received consulting fees lecture fees and reimbursement for attending meetings from Servier GlaxoSmithKline MSD Theramex Galapagos and Rottarpham JeanYves Reginster has received consulting fees or paid advisory boards from Servier Novartis Negma Ely Lilly Wyeth Amgen GlaxoSmthKline Roche Merkle Nycomed NPS Theramex lecture fees when speaking from Merck Sharp and Dohme Eli Lilly Rottapharm IBSA Genevrier Novartis Servier Roche GlaxoSmithKline Teijin Teva Ebewee Pharma Zodiac Analis Theramex Nycomed and NovoNordisk grant support from Bristol Myers Squibb Merck Sharp Dhome Rottapharm Teva Eli Lilly Novartis Roche GlaxoSmithKline Amgen and Servier


Keywords:

References


.
Search In Abstract Of Papers:
Other Papers In This Journal:

  1. Development of an electronic medical record based intervention to improve medical care of osteoporosis
  2. Morbidity following lower extremity fractures in men with spinal cord injury
  3. DXA-based hip structural analysis of once-weekly bisphosphonate-treated postmenopausal women with low bone mass
  4. Effects of 25-hydroxyvitamin D level and its change on parathyroid hormone in premenopausal Chinese women
  5. Thalassemia bone disease: the association between nephrolithiasis, bone mineral density and fractures
  6. Evaluation of three risk assessment tools in discriminating fracture status among Chinese patients undergoing hemodialysis
  7. Oral bisphosphonates and risk of ischemic stroke: a case–control study
  8. The association between serum osteocalcin levels and metabolic syndrome in Koreans
  9. Place of residence and risk of fracture in older people: a population-based study of over 65-year-olds in Cardiff
  10. Fracture risk and adjuvant hormonal therapy among a population-based cohort of older female breast cancer patients
  11. Effects of therapeutic exercise for persons with osteoporotic vertebral fractures: a systematic review
  12. Genetic analysis of serum osteocalcin and bone mineral in multigenerational Afro-Caribbean families
  13. Effect of hospitalist consultation on treatment of osteoporosis in hip fracture patients
  14. Declining incidence of low-trauma knee fractures in elderly women: nationwide statistics in Finland between 1970 and 2006
  15. Changing health behaviors with social marketing
  16. Selective protein depletion impairs bone growth and causes liver fatty infiltration in female rats: prevention by Spirulina alga
  17. The vertebral fracture cascade in osteoporosis: a review of aetiopathogenesis
  18. Clinical performance of osteoporosis risk assessment tools in women aged 67 years and older
  19. Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database
  20. One year outcomes and costs following a vertebral fracture
  21. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study
  22. Classification of women with and without hip fracture based on quantitative computed tomography and finite element analysis
  23. Influence of age and sex steroids on bone density and geometry in middle-aged and elderly European men
  24. The relationship of vitamin D status to bone mineral density in an Italian population of postmenopausal women
  25. Effects of a combined alendronate and calcitriol agent (Maxmarvil®) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study
  26. Tracking of size-adjusted bone mineral content and bone area in boys and girls from 10 to 17 years of age
  27. Vertebral Scheuermann’s disease in Europe: prevalence, geographic variation and radiological correlates in men and women aged 50 and over
  28. Age-related hyperkyphosis, independent of spinal osteoporosis, is associated with impaired mobility in older community-dwelling women
  29. Performance of COLIA1 Polymorphism and Bone Turnover Markers to Identify Postmenopausal Women with Prevalent Vertebral Fractures
  30. Economic burden of privately insured non-vertebral fracture patients with osteoporosis over a 2-year period in the US
  31. Vitamin D status in men with psoriatic arthritis: a case-control study
  32. Long-term treatment of osteoporotic women with bisphosphonates does not impair the response to subsequently administered intravenous pamidronate
  33. Treatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE US™
  34. Combining clinical factors and quantitative ultrasound improves the detection of women both at low and high risk for hip fracture
  35. De novo autoimmune hepatitis associated with PTH(1–34) and PTH(1–84) administration for severe osteoporosis in a liver transplant patient
  36. Basic fibroblast growth factor has rapid bone anabolic effects in ovariectomized rats
  37. Precision of 18 F-fluoride PET skeletal kinetic studies in the assessment of bone metabolism
  38. RETRACTED ARTICLE: Nitrate use and changes in bone mineral density: the Canadian Multicentre Osteoporosis Study
  39. Clinical characteristics and risk factors of postoperative pneumonia after hip fracture surgery: a prospective cohort study
  40. Quantitative ultrasound and fracture risk prediction in non-osteoporotic men and women as defined by WHO criteria
  41. Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg
  42. Serum sclerostin: the missing link in the bone-vessel cross-talk in hemodialysis patients?
  43. Lack of response to teriparatide therapy for bisphosphonate-associated osteonecrosis of the jaw: reply to Subramanian and Quek
  44. The Presence and Severity of Vertebral Fractures is Associated with the Presence of Esophageal Hiatal Hernia in Postmenopausal Women
  45. Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden
  46. Influence of fall related factors and bone strength on fracture risk in the frail elderly
  47. Discriminative value of FRAX for fracture prediction in a cohort of Chinese postmenopausal women
  48. Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism
  49. Stroke in relation to use of raloxifene and other drugs against osteoporosis
  50. Milk ribonuclease-enriched lactoferrin induces positive effects on bone turnover markers in postmenopausal women
  51. The relationship between low bone mass and metabolic syndrome in Korean women
  52. Effect of high-dose cholecalciferol (vitamin D 3 ) on bone and body composition in children and young adults with HIV infection: a randomized, double-blind, placebo-controlled trial
  53. Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence
  54. Treatment of osteoporosis after alendronate or risedronate
  55. Vertebral anti-fracture efficacy of strontium ranelate according to pre-treatment bone turnover
  56. Estrogen receptor α CA dinucleotide repeat polymorphism is associated with rate of bone loss in perimenopausal women and bone mineral density and risk of osteoporotic fractures in postmenopausal women
  57. Bone mass following physical activity in young years: a mean 39-year prospective controlled study in men
  58. Fracture Reduction Affects Medicare Economics (FRAME): Impact of increased osteoporosis diagnosis and treatment
  59. Low skeletal muscle mass associates with low femoral neck strength, especially in older Korean women: the Fourth Korea National Health and Nutrition Examination Survey (KNHANES IV)
  60. Age-related differences in the activity of arterial mineral deposition and regional bone metabolism: a 18 F-sodium fluoride positron emission tomography study
  61. Copper deficit as a potential pathogenic factor of reduced bone mineral density and severe tooth wear
  62. Has Choosing Wisely® affected rates of dual-energy X-ray absorptiometry use?
  63. RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction
  64. Sensitivity and specificity of radiographic characteristics in atypical femoral fractures
  65. The interaction of ethnicity and chronic disease as risk factors for osteoporotic fractures: a comparison in Canadian Aboriginals and non-Aboriginals
  66. Association between osteocalcin and glucose metabolism: a meta-analysis
  67. Decreased serum sclerostin levels in patients with primary hyperparathyroidism: a cross-sectional and a longitudinal study
  68. Targeted education improves the very low recognition of vertebral fractures and osteoporosis management by general internists
  69. Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis
  70. Evaluation of panoramic radiomorphometric indices related to low bone density in sickle cell disease
  71. Morphological changes of injected calcium phosphate cement in osteoporotic compressed vertebral bodies
  72. Both resistance and agility training reduce back pain and improve health-related quality of life in older women with low bone mass
  73. Homocysteine and fracture risk in postmenopausal women: the OFELY study
  74. Excess mortality following hip fracture: a systematic epidemiological review
  75. A double-blind, randomized, Phase III, multicenter study in 358 pediatric subjects receiving isotretinoin therapy demonstrates no effect on pediatric bone mineral density
  76. Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX™)
  77. Weight loss and distal forearm fractures in postmenopausal women
  78. Implementation of osteoporosis guidelines: a survey of five large fracture liaison services in the Netherlands
  79. Systemic treatment with strontium ranelate promotes tibial fracture healing in ovariectomized rats
  80. Systemic treatment with strontium ranelate promotes tibial fracture healing in ovariectomized rats
  81. BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial

Search Result: